Paediatric respiratory reviews · 2026
The need to restudy SABA regimens on discharge of children with an acute asthma exacerbation: A scoping review.
СтатьяScoping ReviewНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yong Deborah Yujie, Thomas Biju, Elnazir Basil
Аннотация
BACKGROUND: This scoping review examines the recommendations for short-acting beta-agonists (SABA) in discharge and weaning plans following acute asthma exacerbations in children. It focuses on SABA overprescription in discharge/weaning plans after acute asthma exacerbations and explores strategies to promote protocol-directed care.
METHODS: National and institutional protocols from the USA, UK, Australia, Canada, and Singapore between 2000 and 2025 were reviewed. Data on SABA weaning plan recommendations, initial dosage, frequency, duration, and caregiver instructions were extracted and analysed using descriptive statistics. Searches were conducted from December 2024 to August 2025.
RESULTS: Significant variability in protocols was found, with no randomised controlled trials or systematic reviews supporting current SABA discharge/weaning practices, highlighting a lack of evidence-based recommendations.
CONCLUSIONS: There is an urgent need for RCTs to guide safe SABA use. Improved patient education, access to inhaled corticosteroids, and evidence-based discharge plans are key to reducing SABA overuse and improving paediatric asthma outcomes.
METHODS: National and institutional protocols from the USA, UK, Australia, Canada, and Singapore between 2000 and 2025 were reviewed. Data on SABA weaning plan recommendations, initial dosage, frequency, duration, and caregiver instructions were extracted and analysed using descriptive statistics. Searches were conducted from December 2024 to August 2025.
RESULTS: Significant variability in protocols was found, with no randomised controlled trials or systematic reviews supporting current SABA discharge/weaning practices, highlighting a lack of evidence-based recommendations.
CONCLUSIONS: There is an urgent need for RCTs to guide safe SABA use. Improved patient education, access to inhaled corticosteroids, and evidence-based discharge plans are key to reducing SABA overuse and improving paediatric asthma outcomes.